breast cancer
Conditions
Interventions
None listed
Sponsors
The First Affiliated Hospital of Xinxiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Cohort 1 Aged >= 18 years at the time of enrollment; Histologically confirmed HER2+ breast cancer; Newly diagnosed or completed definitive early breast surgery; Complete medical history information. Cohort 2 Age >= 18 years at the time of enrollment; Histologically confirmed HR+ HER2- breast cancer; Newly diagnosed or completed definitive early breast surgery; Complete medical history information. Cohort 3 Age >= 18 years at the time of enrollment; Histologically confirmed HER2+ breast cancer; De Novo or recurrent metastatic breast cancer; Complete medical history information. Cohort 4 Age >= 18 years at the time of enrollment; Histologically confirmed HR+ HER2- breast cancer; De Novo or recurrent metastatic breast cancer; Complete medical history information.
Exclusion criteria
Exclusion criteria: Cohort 1 Participated in other Intervention drug clinical trials within 4 weeks before admission. Cohort 2 Participated in other Intervention drug clinical trials within 4 weeks before admission. Cohort 3 Patients with HER2 + advanced breast cancer who have received more than 2 lines of therapy; Participated in other Intervention drug clinical trials within 4 weeks before admission. Cohort 4 Patients with HR+ HER2- advanced breast cancer who have received more than 2 line of therapy; Participated in other Intervention drug clinical trials within 4 weeks before admission.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To describe the treatment pattern on HER2+ & HR+HER2- early and advanced breast cancer in county; | — |
Secondary
| Measure | Time frame |
|---|---|
| To describe the referral behavior in county (Among all patients);To explore the relationship between recurrent risk and OFS, chemotherapy and OFS;To explore the duration of medical OFS in early breast cancer;To explore the duration of anti-HER2 therapy in advanced breast cancer; | — |
Countries
China
Contacts
Public ContactPing Lu
The First Affiliated Hospital of Xinxiang Medical College
Outcome results
None listed